Phillip Bosua - 14 Dec 2022 Form 4 Insider Report for KNOW LABS, INC. (KNW)

Role
CEO and President, Director, 10%+ Owner
Signature
/s/ Phillip A. Bosua
Issuer symbol
KNW
Transactions as of
14 Dec 2022
Transactions value $
$0
Form type
4
Filing time
19 Dec 2022, 15:14:10 UTC
Previous filing
21 Dec 2021
Next filing
15 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KNW Common Stock 3,005,000 14 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNW Option to Purchase Common Stock Award $0 +1,250,000 $0.000000 1,250,000 14 Dec 2022 Common Stock 1,250,000 $1.41 Direct F4
holding KNW Option to Purchase Common Stock 1,000,000 14 Dec 2022 Common Stock 1,000,000 $1.28 Direct F1
holding KNW Option to Purchase Common Stock 1,200,000 14 Dec 2022 Common Stock 1,200,000 $1.10 Direct F2
holding KNW Option to Purchase Common Stock 4,264,395 14 Dec 2022 Common Stock 4,264,395 $1.53 Direct F3
holding KNW Option to Purchase Common Stock 1,300,000 14 Dec 2022 Common Stock 1,300,000 $2.09 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Option shares vest 25% quarterly over four years beginning 08/01/2018.
F2 Option shares vest upon approval of the Company's blood glucose measurement technology by the U.S. Food and Drug Administration.
F3 Milestone-based Option shares vest upon the Company's successful milestone achievements set forth in two Stock Option Agreements dated 12/15/2020.
F4 Options vest quarterly over four years. Immediate vesting upon the occurrence of a Change-in-Control.